Why the study?
It is not clear from published literature how antithrombotic doses used in clinical practice were derived from preclinical and clinical data, with few large RCTs comparing different doses vs placebo.
Do lower doses of antithrombotic agents maintain efficacy while improving safety compared to standard recommended doses?
Do lower doses of antithrombotic agents maintain efficacy while improving safety compared to standard recommended doses?
This review suggests that lower doses of antithrombotics than currently recommended may offer a better safety profile while maintaining efficacy.
Answers are grounded in this paper and cite their sources.
Current antithrombotic dosing may prioritize noninferiority success over optimal balance; leaves open the need for dedicated dose-finding RCTs.
The clinical doses of antithrombotics-antiplatelet and anticoagulant agents-need to balance efficacy and safety. It is not clear from the published literature how the doses currently used in clinical practice have been derived from preclinical and clinical data. There are few large randomised controlled trials (RCTs) that compare outcomes with different doses vs placebo. For newer antithrombotics, RCT doses appear to have been chosen to maximise the probability of demonstrating noninferiority when compared to established agents such as warfarin or clopidogrel. Data from RCTs show that aspirin is an effective antithrombotic at doses below 75 mg daily, and that direct oral anticoagulants reduce the risk of stroke in patients with coronary disease at doses 1/4 of those recommended in atrial fibrillation. Lower doses than those currently recommended are safer and still maintain substantial efficacy.
No takes yet. Share an insight, caveat, or question.
Dimmitt et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: